Dr. Timothy Schulz-Utermoehl
Angestellt, Chief Operating Officer, Pandeia Therapeutics Limited
Oxford, United Kingdom, Vereinigtes Königreich
Werdegang
Berufserfahrung von Timothy Schulz-Utermoehl
Bis heute 4 Jahre und 7 Monate, seit Okt. 2019
Chief Operating Officer
Round Earth Therapeutics
Bis heute 4 Jahre und 8 Monate, seit Sep. 2019
Chief Operating Officer
Pandeia Therapeutics Limited
Bis heute 4 Jahre und 8 Monate, seit Sep. 2019
Cofounder and NED
Pencil Biosciences Ltd
Bis heute 6 Jahre und 2 Monate, seit März 2018
Co-founder and NED
Pedanius Therapeutics Limited
Bis heute 7 Jahre und 5 Monate, seit Dez. 2016
Co-founder and NED
Belfry Therapeutics Limited
4 Jahre und 4 Monate, Sep. 2016 - Dez. 2020
Vice President, Preclinical Development
Chronos Therapeutics Limited
5 Jahre und 2 Monate, Dez. 2014 - Jan. 2020
Director, Head of DMPK
Sygnature Discovery Limited
2 Jahre und 11 Monate, Apr. 2011 - Feb. 2014
Director (DMPK), Exploratory Projects
Shire Pharmaceuticals
3 Monate, Feb. 2011 - Apr. 2011
Acting ADME Section Head, Oncology iMed DMPK
AstraZeneca
5 Jahre, März 2006 - Feb. 2011
Group Manager, In Vitro ADME, Clinical Pharmacology & DMPK
AstraZeneca
Leadership • Successfully provided leadership to a team of up to 11 graduates and postgraduates • Chaired the in vitro PK science network for global CPD • Attended AZ High Impact Leadership Skills (HILS), Constructive Conversations, Employee Relations and Finance for Managers workshops • Led the execution and delivery of the ADME group’s project resource forecasting figures for the quarterly Business Updates • Led a global group in the review of the in vitro ADME competencies and capabilities of CROs
2 Jahre und 5 Monate, Sep. 2003 - Jan. 2006
Senior Research Scientist
Merck Sharp & Dohme
Supported the delivery of DMPK packages for pre-clinical candidates. This included analysing, interpreting and reporting in vitro and in vivo metabolism, in vivo pharmacokinetic and radiolabeled animal ADME studies. In addition, as site member of Merck’s DMPK global scientific task force on drug transporters, CYP450 inhibition and bioactivation, collaborated with site and global colleagues to establish global scientific strategies for the DMPK organisation
1 Jahr und 11 Monate, Okt. 2001 - Aug. 2003
Group Leader, in vitro metabolism and transporters
Merck Sharp & Dohme
Provided expert leadership in the application of drug metabolism and transporter assays within Discovery DMPK. Led a team of two postgraduates.
Postdoctoral Research Scientist within DMPK Discovery & Preclinical Development
Ausbildung von Timothy Schulz-Utermoehl
1996 - 1999
Biochemistry
Imperial College of the University of London
1994 - 1995
Toxicology
Royal Postgraduate Medical School of the University of London
1991 - 1994
Pharmacology/Physiology
University of Leeds
Biochemistry
1989 - 1991
United World College of South East Asia
Sprachen
Englisch
Muttersprache
Deutsch
Fließend